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Background: A decline in mortality rates due to cardiovascular diseases and all-cause mortality has led to increased
life expectancy in the Western world in recent decades. At the same time, the prevalence of type 2 diabetes, a
disease associated with a twofold excess risk of cardiovascular disease and mortality, has been increasing. The
objective of this study was to estimate the secular trend of cardiovascular and all-cause mortality rates in two
population-based cohorts of older persons, with and without type 2 diabetes, examined 11 years apart.
Methods: 1506 participants (42% men) from the population-based Reykjavik Study, examined during 1991–1996
(median 1993), mean age 75.0 years, and 4814 participants (43% men) from the AGES-Reykjavik Study, examined
during 2002–2006 (median 2004), mean age 77.2 years, age range in both cohorts 70–87 years. The main outcome
measures were age-specific mortality rates due to cardiovascular disease and all causes, over two consecutive 5.7- and
5.3-year follow-up periods.
Results: A 32% decline in cardiovascular mortality rate and a 19% decline in all-cause mortality rate were observed
between 1993 and 2004. The decline was greater in those with type 2 diabetes, as illustrated by the decline in the
adjusted hazard ratio of cardiovascular mortality in individuals with diabetes compared to those without diabetes, from
1.88 (95% CI 1.24-2.85) in 1993 to 1.46 (95% CI 1.11-1.91) in 2004. We also observed a concurrent decrease in major
cardiovascular risk factors in both those with and without diabetes. A higher proportion of persons with diabetes
received glucose-lowering, hypertensive and lipid-lowering medication in 2004.
Conclusions: A decline in cardiovascular and all-cause mortality rates was observed in older persons during the period
1993–2004, in both those with and without type 2 diabetes. This decline may be partly explained by improvements in
cardiovascular risk factors and medical treatment over the period studied. However, type 2 diabetes still persists as an
independent risk factor for cardiovascular mortality.
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Life expectancy has increased in the Western world over
recent decades, due in part to a decline in cardiovascular
and all-cause mortality rates [1]. However, there has
been a concurrent increase in the prevalence of type 2
diabetes [2,3], and the well-established twofold excess
risk for coronary heart disease, stroke and mortality
associated with diabetes [4] has led to the question of
whether those with type 2 diabetes have also benefited
from the general decline in mortality risk over recent
decades.
Several studies on the secular change in mortality rate
in recent decades have shown improved life expectancy
in both those with and without type 2 diabetes. In the
Hunt Study carried out in Norway a strong general re-
duction in mortality due to coronary heart disease was
observed between 1984 and 1997, but the more than
twofold higher mortality rate associated with diabetes
persisted over the same period [5]. Similar results were
found in the annual Swedish Living Conditions Survey
conducted between 1980 and 2004 [6]. Based on the
three consecutive NHANES studies between 1971 and
2000, Gregg and co-workers concluded that reduced
mortality rates among persons with diabetes had been
limited to men [7]. In a population-based study con-
ducted at the Mayo Clinic during 1970–1994, mortality
rates for those with and without diabetes declined by
13.8% and 21.4%, respectively, although the mortality
burden associated with diabetes increased significantly
[8], probably due to an increasing incidence of diabetes.
In the most recent study by Gregg and co-workers based
on data from the US National Health Interview Survey,
death rates in both men and women with diabetes were
found to decline substantially between 1997 and 2006,
reducing the absolute difference between adults with
and without diabetes [9]. Results from the United King-
dom General Practice Research Database likewise showed
a decline in relative mortality, that is, the ratio of mortality
rates in study and reference populations, for those diag-
nosed with type 2 diabetes in both men and women in the
UK between 1996 and 2006 [10]. The decline in mortality
parallels the improvement in levels of cardiovascular risk
factors [11], together with improvements in the quality of
care and medical treatment for patients with diabetes [12].
In a study on mortality due to coronary heart disease
associated with type 2 diabetes in Iceland over the
period 1967–1991, the relative risk of death at a mean
age of 55 years was found to be 2.0 for men and 2.4 for
women, compared to those without diabetes [13]. In the
present study, we compared the total and cardiovascular
mortality rates in two population-based cohorts of older
persons, examined 11 years apart, to determine whether
those with type 2 diabetes had fared similarly to those
without diabetes. The two cohorts were taken from thepopulation-based Reykjavik Study (RS) and the Age, Gene/
Environment Susceptibility-Reykjavik (AGES-Reykjavik)
Study, in which changes in cardiovascular risk factors,
treatment modalities and mortality rates are monitored.
Methods
Study population
In brief, the Reykjavik Study is a population-based co-
hort study established in 1967 by the Icelandic Heart
Association as a long-term prospective cardiovascular
survey. Out of a random sample of 30 795 men and
women, born from 1907 to 1935 and living in Reykjavik
in December 1966, 27 281 were invited to participate,
while the remaining 3514 were used as a reference
group. A total of 19 381 participated between the years
1967 and 1996, resulting in a 71% recruitment rate. The
study sample was divided into six groups and examined
in six consecutive stages, as described in detail elsewhere
[14,15]. In this study, we report results only from the last
stage of the Reykjavik Study (N = 1607), including 1506
older individuals, with an age span of 70–87 years. In
the AGES-Reykjavik Study [16], 5764 survivors of the
original cohort who had previously participated in the
Reykjavik Study were re-examined and 4814 fell within
the defined age span. Almost 500 of these (494) had also
participated in the last stage of the Reykjavik Study. The
first cohort, consisting of 1506 participants (42% men),
mean age 75.0 years, was examined between 1991 and
1996 (median 1993), with a median follow-up period of
5.7 years, until mid-2000. The median year of birth was
1919 (inter-quartile range 1917–1921). The second co-
hort, examined 11 years later, consisting of 4814 partici-
pants (43% men), mean age 77.2 years, was examined
between 2002 and 2006 (median 2004), with a median
follow-up period of 5.3 years, until the end of 2009. The
median year of birth was 1927 (inter-quartile range
1923–1931). Informed consent was obtained from all
participants.
As part of the baseline examination in both cohorts, a
comprehensive questionnaire was administered. The
Reykjavik Study participants were asked specific ques-
tions about medication, while participants in the AGES-
Reykjavik Study were asked to bring all medication and
supplements used during the previous 2 weeks to the
clinic to be recorded. Participants not completing the
questionnaire about diabetes (RS: 2; AGES: 53) and
those with incomplete data for other study variables (RS:
97; AGES: 47) were excluded.
The criteria used for the diagnosis of type 2 diabetes in
both cohorts were fasting serum glucose of ≥7 mmol/l
upon arrival at the clinic, based on the WHO recommen-
dations from 1999 [17], self-reported diabetes in the ques-
tionnaire and/or use of diabetes medication. Participants
reporting the onset of diabetes before the age of 40 (RS: 2;
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duals with type 1 diabetes from the study.
Blood samples were drawn after overnight fasting. In
the Reykjavik Study, total cholesterol, HDL cholesterol,
triglycerides and glucose were analysed on a COBAS
Mira instrument. HbA1c was not analysed in the Reykja-
vik Study. In the AGES-Reykjavik Study, total choles-
terol, HDL cholesterol, triglycerides, C-reactive protein
(CRP), glucose and HbA1c were analysed on a Hitachi
912 instrument. Both instruments and reagents were
from Roche Diagnostics and analyses performed accord-
ing to the manufacturer’s instructions.
Blood pressure (BP) was measured with a mercury
sphygmomanometer with a large cuff, and the mean
value of two consecutive blood pressure measurements
was used in the analysis. Height and weight were mea-
sured and body mass index (BMI) calculated (kg/m2).
Information on cause of death was based on data from
a complete adjudicated registry of cause of death avail-
able from the Icelandic National Roster [18]. Mortality
due to cardiovascular disease was defined according to
ICD 9–10 (defined as in the SCORE project [19]). In the
present study, the duration of an individual’s exposure to
risk was calculated from the date of participation in the
baseline survey until the date of death from cardiovascu-
lar disease or from all causes, or until the end of the
follow-up period in each of the two cohorts. Prevalent
coronary heart disease was defined as a history of myo-
cardial infarction (ICD 9–10: 410 and I21), percutaneous
coronary intervention or coronary artery bypass grafting
(coded according to the NOMESCO classification for
Surgical Procedures) and was obtained from hospital
records, collected from National Health Service Records
by the Icelandic Heart Association.
The study was approved by the National Bioethics
Committee in Iceland (VSN: 00–063), as well as the In-
stitutional Review Board of the Intramural Research Pro-
gram of the National Institute on Aging and the Data
Protection Authority in Iceland.
Statistical analyses
The baseline characteristics of the participants from the
two cohorts were compared by sex and diabetic status,
using either linear or logistic regression with age adjust-
ment. Skewed variables were log-transformed. The Cox
proportional hazards regression model was used to esti-
mate hazard ratios and mortality rates using 2-way inter-
action terms between sex, period, and type 2 diabetes
status. Time since entering the study was used as the
time scale. In addition to the interaction terms, adjust-
ment was made for age, hypertensive and lipid-lowering
medication, prevalent coronary heart disease and for car-
diovascular risk factors: total cholesterol, HDL choles-
terol, systolic blood pressure, BMI, triglycerides andsmoking history. The mortality rate was estimated from
the cumulative hazard function after 5 years’ follow-up,
and expressed as the rate per 1000 person years. Using
interactions allows separate estimates of mortality rates
and hazard ratios by sex, diabetes status and study
period from the same model and also overall results by
weighing together the appropriate contrasts. The pro-
portionality assumption for the hazard ratio associated
with type 2 diabetes was inspected graphically and ana-
lysed as a time-dependent covariate by testing the sig-
nificance of the interaction of type 2 diabetes status
with the logarithm of the follow-up of time. Signifi-
cance testing was two-sided and based on a 5% prob-
ability level.
When comparing estimates between cohorts, all p-values
and confidence intervals were reported from bootstrap
estimates based on 200 replications (using independent
sampling stratified by cohort) as 494 participants in the
Reykjavik Study were alive and participated in the AGES-
Reykjavik Study. Naïve estimates of differences between
cohorts (treating samples as independent), may then lead
to too narrow confidence bands. These estimates are also
given for comparison. Sensitivity analysis was also per-
formed by removing overlapping participants (N = 494)
from the AGES-Reykjavik cohort. The results were not
affected by removing the overlapping participants and are
not shown. The change in mortality rate between 1993 and
2004, based on official data from Statistics Iceland, was
estimated by applying a Poisson regression model to the
age-specific number of deaths for the age range 70 to 87.
The model included age, age2, sex and a binary indicator
for the two periods. The number of alive individuals (mid-
year) divided according to age and sex was used as a log
offset. The data were analysed using SAS/STATW software,
version 9.2 and Stata version 12.
Results
Changes in cardiovascular risk factors and medication
between 1993 and 2004
A significant decrease was observed in the levels of the
major cardiovascular risk factors (total cholesterol, tri-
glycerides, systolic blood pressure and smoking) between
the study periods in both men and women, together
with a significant increase in HDL cholesterol, BMI and
hypertensive and lipid-lowering medication. The cohorts
were then divided into persons with and without dia-
betes. Individuals with type 2 diabetes had consistently
higher baseline levels of triglycerides, BMI and systolic
blood pressure at both time points than those without
diabetes. Total cholesterol levels, however, were lower in
those with type 2 diabetes, significantly so in the AGES
cohort, as can be seen in Table 1.
In 1993 the prevalence of coronary heart disease,
obtained from hospital records, was similar in those with
Table 1 Baseline characteristics of the older men and women with (T2D Yes) and without type 2 diabetes (T2D No) included in this study
Men Women
Variable Reykjavik Study AGES-Reykjavik Reykjavik Study AGES-Reykjavik
1993 2004 1993 2004
Mean ± SD, IQR or% T2D No T2D Yes T2D No T2D Yes T2D No T2D Yes T2D No T2D Yes
Number 530 106 1738 330 792 78 2471 275
Age, years 74.7 (±3.5) 74.1 (±3.3) * 77.0 (±4.5) 77.1 (±4.4) 75.3 (±3.6) 75.7 (±4.1) 77.3 (±4.7) 77.9 (±4.5)*
Total cholesterol, mmol/l 6.01 (±1.05) 5.91 (±1.12) 5.23 (±1.07) 4.92 (±1.12) *** 7.03 (±1.25) 6.97 (±1.18) 6.00 (±1.10) 5.53 (±1.13) ***
HDL cholesterol, mmol/l 1.14 (±0.31) 1.05 (± 0.35) * 1.42 (±0.40) 1.25 (±0.32) *** 1.52 (±0.41) 1.34 (±0.47) *** 1.74 (±0.44) 1.52 (±0.43) **
TG mmol/l, median (IQR) 1.07 (±0.61) 1.43 (1.05) *** 0.98 (0.57) 1.30 (0.88) *** 1.21 (0.66) 1.80 (1.30) *** 1.05 (0.64) 1.40 (0.84) ***
CRP mg/l, median (IQR) - - 1.80 (2.60) 1.90 (2.70) - - 1.90 (2.90) 2.80 (4.60)
BMI, kg/m2 25.9 (±3.6) 27.5 (±3.9) *** 26.5 (±3.7) 28.4 (±4.1) *** 26.2 (±4.5) 29.1 (±6.1) *** 26.9 (±4.7) 29.5 (±5.2) ***
Systolic BP, mm Hg 150 (±22) 159 (± 26) ** 142 (±20) 145 (±21) * 148 (±21) 152 (±19) 142 (±21) 144 (±21)
Diastolic BP, mm Hg 85 (±10) 88 (± 11) ** 76 (±11) 75 (±11) ** 80 (±10) 81 (± 11) 72 (± 9) 70 (±10) **
Hypertension (%)a 79.2 85.8 77.8 91.1 75.0 85.9 81.3 91.9 ***
Hypertensive medication (%) 26.8 35.8 59.2 79.7*** 34.8 48.7* 63.8 83.8 ***
Lipid-lowering medication (%) 1.9 2.8 27.3 37.7 2.0 0 17.7 37.0***
Prevalence of CHD (%)b 17.4 17.0 24.8 31.8** 4.6 5.1 8.3 14.0*
Prevalence of MI (%)c 13.4 13.2 12.4 14.6 3.9 3.9 4.6 7.6
Family history of MI (%) 26.0 21.7 34.1 37.7** 29.3 32.1 42.6 49.8 **
Current smoker (%) 17.6 20.8 11.0 9.2 17.6 11.5 12.5 9.8
Haemoglobin A1c (%) - - 5.55 (±0.31) 6.44 (±0.83) *** - - 5.61 (±0.32) 6.42 (±0.88) ***
Glucose, mmol/l 5.77 (±0.48) 8.16 (±2.01) *** 5.58 (±0.51) 7.91 (±2.16) *** 5.51 (±0.56) 7.79 (±2.24) *** 5.43 (±0.51) 7.73 (±2.09) ***
Significance estimates: *p < .05; **p < .01; *** p < .001 for age-adjusted comparison between the Reykjavik Study and the AGES- Reykjavik Study.
aHypertension, those with systolic BP > 140 mmHg, diastolic BP > 90 mm Hg or on hypertensive medication.
bPrevalence of CHD, from hospital records, of those with history of myocardial infarction (MI), percutaneous coronary intervention, and coronary-artery bypass grafting.
cPrevalence of MI, from hospital records, of those with history of MI.
BMI: body mass index; BP: blood pressure; CHD: coronary heart disease; CRP: C-reactive protein; TG: triglyceride.
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http://www.biomedcentral.com/1471-2458/13/36and without type 2 diabetes for both sexes, i.e., about
17% in men and 5% in women. In 2004, however, the
prevalence of coronary heart disease in those with dia-
betes had risen to 32% in men and 14% in women, com-
pared to 25% in men and 8% and women without
diabetes. During this period, little change was seen in
the prevalence of myocardial infarction, except in
women with diabetes, where almost twice as many had
experienced a myocardial infarction in 2004 than in
1993 (Table 1).
An increase in hypertensive medication observed be-
tween 1993 and 2004 was more marked in individuals
with diabetes than in those without, although increases
were seen in all groups (Table 1). Over the same period,
the observed decrease in mean values of systolic blood
pressure was greater in men and women with diabetes
than in those without (Table 1).
Use of statins was not reported in the 1993 study,
while other lipid-lowering medication was used by 3% of
individuals with known diabetes and by under 2% of all
participants. In 2004 about 44% of individuals with
known diabetes were taking statins, but only 27% of the
men and 18% of the women without diabetes were statin
users. Individuals using statins had 1.26 (95% CI 1.19-
1.32) mmol/l lower mean total cholesterol levels, irre-
spective of their diabetic status.
The prevalence of type 2 diabetes was about the same
in both cohorts, as can be seen in Table 2: 16.7% and
16.0% in men and 9.0% and 10.0% in women, in 1993Table 2 Prevalence of type 2 diabetes (T2D) and glucose-lowe
Reykjavik Study 1991–1996 (median 1993) Men
N = 636
Total T2D, prevalence % (n) 16.7 (106)
Diagnosed at baseline % (n) 10.5 (67)
With prior T2D diagnosis % (n) 6.1 (39)
Mean T2D duration in years (±SD)
Glucose-lowering treatment in patients with
prior T2D diagnosis
% on glucose-lowering medication (n) 59 (23)
% on special diet only (n) 41 (16)
AGES-Reykjavik 2002–2006 (median 2004) Men
N = 2068
Total T2D, prevalence % (n) 16.0 (330)
Diagnosed at baseline % (n) 4.7 (97)
With prior T2D diagnosis % (n) 11.3 (233)
Mean T2D duration in years (±SD)
Glucose-lowering treatment in patients with
prior T2D diagnosis
% on glucose-lowering medication (n) 76 (161)
% on special diet only (n) 24 (52)and 2004, respectively. The proportion of individuals
already diagnosed as having type 2 diabetes at baseline
increased from 41% in 1993 to 69% in 2004, as did the
proportion of individuals already diagnosed and receiv-
ing glucose-lowering medication. In 1993 only 59% of
men with prior diagnosis of type 2 diabetes were on
glucose-lowering medication, compared to 76% in 2004.
Similarly, 31% of women diagnosed with type 2 diabetes
in 1993 were on glucose-lowering medication compared
to 70% in 2004 (Table 2).
Changes in cardiovascular and all-cause mortality rates
between 1993 and 2004
Between the last stage of the Reykjavik Study (1993) and
the AGES-Reykjavik Study (2004), the secular decline in
cardiovascular mortality rates observed in older indivi-
duals (aged 70–87 years) was 32% (95% CI 14%-45%)
and in all-cause mortality rates 19% (95% CI 6%-30%),
as illustrated in Figure 1. Rates were adjusted to age
75, sex (male 43%), the mean levels of cardiovascular
risk factors (total cholesterol, HDL cholesterol, systolic
blood pressure, BMI, triglycerides and smoking his-
tory), and hypertensive and statin medication within
each cohort.
To evaluate the contribution of changes in the level of
risk factors and medication between study periods, the
mortality rates were compared after adjusting for the
common mean values of the these factors over cohorts.
Moderate attenuation was seen and the decline estimatedring treatment in the two study cohorts
Women Men and women % of total T2D
N = 870 N = 1506
9.0 (78) 12.2 (184) 100
4.8 (42) 7.2 (109) 59
4.1 (36) 5.0 (75) 41
10.1 (±9.4)
31 (11)
69 (25)
Women Men and women % of total T2D
N = 2746 N = 4814
10.0 (275) 12.6 (605) 100
3.0 (83) 3.7 (180) 31
7.0 (192) 8.8 (425) 69
10.7 (±10.0)
70 (112)
30 (48)
Cohort
Reykjavik Study
T2D No
T2D Yes
AGES-Reykjavik
T2D No
T2D Yes
Deaths
139
105
34
397
318
79
N
1506
1322
184
4814
4209
605
Rate
10.7
 9.9
18.9
 7.3
 7.0
10.2
0 5 10 15 20 25 30
CVD mortality rate per 1000 person years
Cohort
Reykjavik Study
T2D No
T2D Yes
AGES-Reykjavik
T2D No
T2D Yes
Deaths
297
241
56
948
782
166
N
1506
1322
184
4814
4209
605
Rate
26.3
25.0
38.5
21.3
20.5
28.5
0 5 10 15 20 25 30 35 40 45 50 55
All cause mortality rate per 1000 person years
A
B
Figure 1 A) Cardiovascular disease (CVD) mortality rate and B) all-cause mortality rate per 1000 person years for older individuals with
(T2D Yes) and without type 2 diabetes (T2D No). Rates were adjusted to age 75, sex and the mean levels of cardiovascular risk factors (total
cholesterol, HDL cholesterol, systolic blood pressure, BMI, triglycerides and smoking history), and hypertensive and statin medication within each
cohort. In the Reykjavik Study (1993) the median follow-up period was 5.7 years and in the AGES-Reykjavik Study (2004) 5.3 years. The vertical
lines represent the mortality rate for the AGES-Reykjavik cohort (N = 4814). The horizontal lines show 95% confidence intervals.
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vascular mortality and 16% (95% CI 1%-29%, bootstrap
2%-28%) for all-cause mortality.
When the decline in mortality was estimated for those
with and without type 2 diabetes, both cardiovascular
(Figure 1A) and all-cause mortality rates (Figure 1B)
declined similarly over the approximately 11 years be-
tween the two studies. The observed decline was greater
in individuals with type 2 diabetes than in those without,
albeit not statistically significant. From 1993 to 2004, a
decline of 46% (95% CI 17% -65%) in cardiovascular
mortality rate was seen in those with diabetes; the rate
falling from 18.9 to 10.2 per 1000 person years. For indi-
viduals without diabetes the decrease in cardiovascular
mortality rate was 29% (95% CI 10%-45%); the rate decreas-
ing from 9.9 to 7.0 per 1000 person years over the same
period. The reduction observed in all-cause mortality rate in
those with type 2 diabetes was 27% (95% CI −10%-46%) and
in those without type 2 diabetes 18% (95% CI 4%-30%).
Interactions between sex and the effect of diabetes sta-
tus were neither significant for cardiovascular mortal-
ity (p = 0.41) nor total mortality (p = 0.51).
The hazard ratios for the relative risk of death from
cardiovascular disease with respect to diabetes were esti-
mated (Table 3). The hazard ratios adjusted for age and
sex, fell from 2.21 (95% CI 1.46-3.34) in the ReykjavikStudy (1993) to 1.69 (95% CI 1.30-2.20) in the AGES-
Reykjavik Study (2004). When additionally adjusted for
cardiovascular risk factors, they fell from 1.88 (95% CI
1.24-2.85) in 1993 to 1.46 (95% CI 1.11-1.91) in 2004.
No further attenuation was seen after additional adjust-
ment for surgical treatment (percutaneous coronary
intervention and coronary-artery bypass grafting), or
hypertensive and statin medication.
The hazard ratios for relative risk of death from all
causes declined from 1.66 (95% CI 1.23-2.25) in 1993 to
1.47 (95% CI 1.23-1.75) in 2004 when adjusted for age and
sex. After additional adjustment for cardiovascular risk
factors, the hazard ratio decreased from 1.55 (95% CI
1.14-2.11) to 1.38 (95% CI 1.15-1.65). This 11% (bootstrap
95% CI −26%-37%, naïve 95% CI −24%-37%) decline in
hazard ratios did not reach statistical significance.
The hazard ratios were also estimated after omitting
data from participants who attended during both study
periods. The hazard ratios for the relative risk of death
from cardiovascular disease, adjusted for age and sex, fell
from 2.15 (95% CI 1.41 - 3.27) in the Reykjavik Study
(1993) to 1.58 (95% CI 1.17 - 2.13) in the AGES-
Reykjavik Study (2004). When additionally adjusted for
cardiovascular risk factors, the hazard ratios fell from
1.82 (95% CI 1.19 - 2.78) in the Reykjavik Study to 1.34
(95% CI 0.98 - 1.83) in the AGES-Reykjavik Study.
Table 3 Hazard ratios (HR) with 95% confidence intervals (CI) for the relative risk of death. Cardiovascular disease
(CVD) mortality and all-cause mortality in individuals with type 2 diabetes (T2D) compared to those without in each
cohort
Adjusted for
age and sex
Adjusted for
age, sex, and
CVD risk factorsa
Adjusted for
age, sex,
CVD risk factorsa,
surgical interventionb,
HTNmed.c
Adjusted for
age, sex,
CVD risk factors a,
surgical interventionb,
HTNmed.c and statin use
HR 95% CI HR 95% CI HR 95% CI HR 95% CI
Death from CVD
Reykjavik Study: with
T2D vs. without T2D
2.21 1.46-3.34 1.88 1.24-2.85 1.89 1.25-2.87 1.89 1.24-2.86
AGES-Reykjavik: with
T2D vs. without T2D
1.69 1.30-2.20 1.46 1.11-1.91 1.46 1.12-1.92 1.47 1.12-1.93
Death from all causes
Reykjavik Study: with
T2D vs. without T2D
1.66 1.23-2.25 1.55 1.14-2.11 1.56 1.15-2.11 1.54 1.13-2.09
AGES-Reykjavik: with
T2D vs. without T2D
1.47 1.23-1.75 1.38 1.15-1.65 1.38 1.15-1.65 1.39 1.16-1.67
aCVD risk factors: total cholesterol, HDL cholesterol, systolic blood pressure, BMI, triglycerides and smoking history.
bSurgical intervention: percutaneous coronary intervention and coronary-artery bypass grafting.
cHTNmed: hypertensive medication.
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causes declined from 1.63 (95% CI 1.20 - 2.21) in 1993 to
1.41 (95% CI 1.15 - 1.72) in 2004 when adjusted for age
and sex. After additional adjustment for cardiovascular risk
factors, the hazard ratio decreased from 1.51 (95% CI 1.10
- 2.06) to 1.30 (95% CI 1.06 - 1.60). This 14% (bootstrap
95% CI −26% - 40%, naïve 95% CI −22% - 39%) decline in
mortality ratio did not reach statistical significance.
Discussion
In this population-based cohort study we observed a de-
cline in mortality rates of older individuals between the two
study periods, together with favourable changes in risk fac-
tors and an increase in medical treatment. The observed
decline in the cardiovascular and all-cause mortality rates
in our study are comparable, according to Statistics Iceland
[18], to the decline seen between 1993 and 2004 for the
same age group in the Icelandic population at large, of 36%
(95% CI 25%-45%) in cardiovascular, and 21% (95% CI
14%-28%) in all-cause mortality rates. As the decline in cor-
onary heart disease mortality over recent decades has been
attributed to a reduction in cardiovascular risk factors [20]
we adjusted for mean values of risk factors and medical
treatment over the two cohorts and found that the esti-
mated cardiovascular mortality rate fell from 32% to 25%,
indicating that the decline in mortality rate is only partly
due to a reduction in cardiovascular risk factors and in-
crease in medical treatment, and therefore remains to be
fully explained.
The decline in both cardiovascular and all-cause mor-
tality rates observed was somewhat greater in individuals
with diabetes than in those without, although the differ-
ence did not reach statistical significance. The age- andsex-adjusted hazard ratio for cardiovascular mortality
declined from 2.21 in 1993 to 1.69 in 2004, and for all-
cause mortality, from 1.66 to 1.47. Compared to the esti-
mated relative risk of death from all causes, between
1967 and 1991, of 1.9 for men and 1.7 for women with
type 2 diabetes, in a middle-aged Icelandic cohort [13],
the hazard ratio for death from all causes in the cohort
of older individuals from 1993 is only slightly lower. The
low number of participants in the 1993 cohort, however,
does not allow a detailed study on the effect of either
disease duration or the difference between men and
women, so the comparison must be made with caution.
The observed attenuation in hazard ratio after adjust-
ing for cardiovascular risk factors did not alter the trend
in hazard ratio reduction between the two time points,
emphasizing that the increased mortality rate of those
with type 2 diabetes persisted over time, and was inde-
pendent of cardiovascular risk factors. Our results are
thus in agreement with those from a collaborative meta-
analysis of 102 prospective studies, that conventional
cardiovascular risk factors do not explain why twice the
incidence of cardiovascular diseases is seen in those
with type 2 diabetes than in those without diabetes [4].
It has been shown that the increased mortality risk for
persons with type 2 diabetes is related to both age at
onset and duration of disease. In an observational study
from Tayside, Scotland, Barnett and co-workers showed
that hazard ratios for mortality decreased with increas-
ing age at diagnosis, and increased mortality risk was
not evident until 2 years after diagnosis [21]. There was
a trend towards increasing risk with increasing duration of
disease, which started to decline 8 years after diagnosis. In
our study the mean duration of disease was just over
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diagnosed at baseline was much higher in the cohort from
1993, i.e. 59% compared to 41% in 2004, so the mean dur-
ation of disease until the end of follow-up was lower in
1993 than in 2004. Increased awareness of the risk of dia-
betes in old age, both among professionals and the gen-
eral public, may be the reason for the increase in
diagnosed diabetes at entry in the AGES-Reykjavik
cohort, and those in the Reykjavik Study cohort may,
therefore, have had untreated disease for some time.
The possible over diagnosis using only one glucose
measurement [22] for newly diagnosed diabetes, may
have led to both a greater dilution bias and a shorter
mean duration of disease in the Reykjavik Study cohort,
and thus underestimation of the mortality rate of diabetic
persons in that cohort.
In the Northern Sweden Monica Study [23] it was
observed that long-term survival after a first myocardial
infarction in middle age was markedly lower in diabetic
patients than in those without diabetes. Similarly, the
long-term survival after the first stroke was much lower
in diabetic patients than in those without diabetes [24],
although survival did improve throughout the period
from 1985 to 2005. The decline in relative mortality due
to diabetes seen between 1996 and 2006 in the UK [10]
possibly resulted from both improved trends in the inci-
dence of and mortality from cardiovascular disease and
improved medical attention. In Denmark reduced rates
of death and cardiovascular disorders were observed in
patients with type 2 diabetes in the Steno-2 Study using
intensive intervention with multiple drug combinations
[25]. Although a general trend towards improved sur-
vival of patients with diabetes compared with those
without diabetes is illustrated in these studies the sur-
vival gap still persists.
Another finding of our study was the increase in
recorded history of acute cases of coronary heart disease
seen between the two periods, in both those with and
without diabetes. This is probably due to the increased
survival rate of coronary heart disease patients, following
the favourable changes in cardiovascular risk factor
levels in all age groups, possibly resulting in milder dis-
ease, but an increase in hospital referral between study
periods cannot be excluded. More intensive medical
intervention has also tended to reduce premature deaths
from coronary heart disease, especially from myocardial
infarction, as was observed in Iceland during the period
1981 to 2006 in the age group of 25–74 years [20].
Regarding the changes in medication over the study
period, we have shown in a previous study that statin
use, irrespective of glucose-lowering or antihypertensive
medication, is associated with lower mortality rate of
older individuals with type 2 diabetes compared to those
without diabetes [26]. In 1993 statin therapy had notbeen introduced and their general use in 2004 could ex-
plain some of the drop in mortality rate observed be-
tween the study periods.
The Icelandic population is comparable to other West-
ern populations with respect to cardiovascular morbidity
and mortality [27], and the low prevalence of diabetes in
Iceland has been changing similarly to trends in other
Western societies [28]. Our data show that the life ex-
pectancy of older individuals diagnosed with type 2 dia-
betes has increased concomitantly with that of the
population in general, and that reductions in cardiovas-
cular risk factors and improved treatment modalities
may have benefited them at least as much as those with-
out diabetes.
The strengths of the present study are the proportion-
ally large national representation of older individuals in
this population-based study, the high participation rate
and the comprehensive information available on morbid-
ity and mortality. It was observed that frailer individuals
participated to a lesser extent, causing a possible bias,
but non-attendees in this study have been shown to have
comparable levels of conventional cardiovascular risk fac-
tors [16] during earlier visits. A weakness of this study is
that the diagnosis of diabetes at baseline was based on a
single measurement of fasting glucose (≥ 7 mmol/l),
thereby possibly causing a positive bias in the number of
persons diagnosed at entry [22]; this may also have caused
a dilution bias in the estimates of mortality rates. Those
developing diabetes after having answered the question-
naire will have been missed, which may have caused a
slight bias in the mortality estimates. The power of the
data was not enough to make stratifying for sex statisti-
cally significant and may be listed as a weakness. Prevalent
coronary heart disease only included acute myocardial in-
farction cases and coronary procedures. Accordingly, sub-
jects with angina were not included, causing a possible
classification bias.
Conclusions
We observed a decline in cardiovascular and all-cause
mortality rates in two population-based cohorts of older
individuals, with and without type 2 diabetes during the
period 1993 to 2004. A decrease in the levels of major
cardiovascular risk factors, together with improved diag-
nosis of diabetes and better medical treatment, is usually
the explanation given for the decline in mortality rate
seen in study populations, and hence the general popula-
tion. The present study, however, shows that type 2 dia-
betes still persists as an independent risk factor for
cardiovascular and all-cause mortality, also in old age.
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